Vascular Therapies Inc., a biotechnology company focused on kidney disease, announced it has appointed a new CEO.
John McDermott, who has more than 30 years of experience in vascular technologies, will head the Cresskill-based company, it announced Wednesday.
“We are very pleased to welcome John as our chief executive officer. John has nearly 30 years of experience in the vascular industry and has led the development and successful commercialization of multiple groundbreaking new technologies. Dr. Sriram Iyer, founder of Vascular Therapies, has done an excellent job leading the company since inception and will continue as its chief scientific officer,” Bob Croce, chairman of the board of directors of Vascular Therapies, Inc, said.
“I am honored to be named as chief executive officer of Vascular Therapies. The company is developing a promising new local vascular drug-delivery technology intended to improve outcomes for patients with advanced kidney disease I look forward to working with the team at Vascular Therapies and collaborating with physicians to provide this important new therapy to patients worldwide,” McDermott said.
Prior to Vascular Therapies, McDermott was CEO of Endologix. Before that, he was the president of Bard Peripheral Vascular, a division of C.R. Bard. He also was the chief operating officer at IMPRA.